Cumberland Pharmaceuticals (CPIX) CFO granted 3,000 stock options

Rhea-AI Filing Summary

Cumberland Pharmaceuticals Vice President and Chief Financial Officer John M. Hamm received a grant of 3,000 stock options on March 18, 2026. These options carry an exercise price of $2.80 per share and expire on March 18, 2036, bringing his reported option holdings to 18,250 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hamm John M.

Role VP Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Options (right to buy)	3,000	$2.80	$8K

Holdings After Transaction: Options (right to buy) — 18,250 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hamm John M.

(Last) (First) (Middle)

1600 WEST END AVENUE, SUITE 1300

(Street)

NASHVILLE TENNESSEE 37203

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (right to buy)	$2.8	03/18/2026		A		3,000		03/18/2030	03/18/2036	Common Stock	3,000	$2.8	18,250	D

Explanation of Responses:

Remarks:

	John Hamm	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CPIX CFO John M. Hamm report on this Form 4?

John M. Hamm, CFO of Cumberland Pharmaceuticals, reported receiving 3,000 stock options as a grant. The options relate to the company’s common stock and represent a compensation award rather than an open-market purchase or sale of existing shares.

What are the key terms of John M. Hamm’s 3,000 Cumberland (CPIX) stock options?

The 3,000 options granted to John M. Hamm have an exercise price of $2.80 per share. They relate to Cumberland’s common stock and carry an expiration date of March 18, 2036, defining how long he may choose to exercise this award.

How many Cumberland (CPIX) options does CFO John M. Hamm hold after this grant?

After the award of 3,000 new options, John M. Hamm is reported to hold 18,250 stock options in total. This figure reflects his aggregate derivative position in company options as shown following the latest transaction entry.

Does the CPIX Form 4 show the CFO buying or selling shares in the market?

The Form 4 shows a grant of 3,000 stock options categorized as a compensation award, not a market trade. There are no open-market purchases or sales of Cumberland common stock reported in this particular insider filing.

Is the Cumberland (CPIX) CFO option grant a routine compensation event?

The transaction is coded as a grant, award, or other acquisition of derivative securities, indicating a compensation-related award. Such option grants are typically part of executive incentive programs rather than discretionary market buying or selling of existing shares.